Tianjin Pharmaceutical Da Ren Tang Group Corporation (600329.SH) subsidiary obtains drug registration certificate for Loxoprofen Sodium Patch.

Tianjin Pharmaceutical Da Ren Tang Group Corporation (600329.SH) announced that its affiliated branch, the Xinxin Pharmaceutical Factory of Tianjin Pharmaceutical Da Ren Tang Group Corporation, recently received the Loxoprofen Sodium Patch Drug Registration Certificate approved and issued by the National Medical Products Administration. The Loxoprofen Sodium Patch uses a new hot-melt patch technology and is an upgraded product of Loxoprofen Sodium Gel Patch. It features being lightweight and thin, comfortable to apply, and strong adhesion, and is used for anti-inflammatory and analgesic treatment of the following diseases and symptoms: osteoarthritis, muscle pain, and swelling or pain caused by trauma. The drug was submitted for registration as a Class 4 chemical drug and, after approval, is deemed to have passed the consistency evaluation. This approval for marketing is another key achievement in the company's strategic layout in the transdermal drug delivery field, marking that the company possesses full-process capabilities in the "R&D-production-quality control" of modern patches represented by gel patches and hot-melt patches. In the future, it will rely on its clinical accumulation in traditional Chinese medicine in the musculoskeletal system field and leverage the technical advantages of transdermal drug delivery preparations to continuously build a modern patch product matrix covering "chemical drugs-traditional Chinese medicines-health patches."